CopyMark Law Group
4.9/5
Drawing for FKB

USPTO serial 79141948

FKB

Reviewed by CopyMark Law Group

Reg. 4779408Status 709
Filing date
Status date
Registration date
Jul 28, 2015
Examiner
CRAWFORD, MARY
Law office
PUBLICATION AND ISSUE SECTION

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with FKB?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Trademark Monitoring
(312) 319-4460
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Start a new application
(312) 319-4460

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Kaushal Odedra

Kaushal Odedra ODEDRA LAW OFFICE, PLLC2020 Pennsylvania Ave, NW #152Washington, DC 20006UNITED STATES

Goods and services

ClassDescriptionStatusFirst use
005Pharmaceutical preparations for use in connection with humans for the treatment of infectious diseases; Pharmaceutical preparations for use in connection with humans for the prevention of infectious diseases; Pharmaceutical preparations for use in connection with humans for the treatment of parasitic diseases; Pharmaceutical preparations for use in connection with humans for the prevention of parasitic diseases; Pharmaceutical preparations for use in connection with humans for the treatment of neoplasms; Pharmaceutical preparations for use in connection with humans for the prevention of neoplasms; Pharmaceutical preparations for use in connection with humans for the treatment of diseases of the blood; Pharmaceutical preparations for use in connection with humans for the prevention of diseases of the blood; Pharmaceutical preparations for use in connection with humans for the treatment of diseases of blood-forming organs; Pharmaceutical preparations for use in connection with humans for the prevention of diseases of blood-forming organs; Pharmaceutical preparations for use in connection with humans for the treatment of diseases of certain disorders involving the immune mechanism; Pharmaceutical preparations for use in connection with humans for the prevention of diseases of certain disorders involving the immune mechanism; Pharmaceutical preparations for use in connection with humans for the treatment of endocrine diseases; Pharmaceutical preparations for use in connection with humans for the prevention of endocrine diseases; Pharmaceutical preparations for use in connection with humans for the treatment of nutritional diseases; Pharmaceutical preparations for use in connection with humans for the prevention of nutritional diseases; Pharmaceutical preparations for use in connection with humans for the treatment of metabolic diseases; Pharmaceutical preparations for use in connection with humans for the prevention of metabolic diseases; Pharmaceutical preparations for use in connection with humans for the treatment of mental disorders; Pharmaceutical preparations for use in connection with humans for the prevention of mental disorders ; Pharmaceutical preparations for use in connection with humans for the treatment of behavioural disorders; Pharmaceutical preparations for use in connection with humans for the prevention of behavioural disorders; Pharmaceutical preparations for use in connection with humans for the treatment of diseases of the nervous system; Pharmaceutical preparations for use in connection with humans for the prevention of diseases of the nervous system; Pharmaceutical preparations for use in connection with humans for the treatment of diseases of the eye; Pharmaceutical preparations for use in connection with humans for the prevention of diseases of the eye; Pharmaceutical preparations for use in connection with humans for the treatment of diseases of eye adnexa; Pharmaceutical preparations for use in connection with humans for the prevention of diseases of eye adnexa; Pharmaceutical preparations for use in connection with humans for the treatment of diseases of the ear; Pharmaceutical preparations for use in connection with humans for the prevention of diseases of the ear; Pharmaceutical preparations for use in connection with humans for the treatment of diseases of the mastoid process; Pharmaceutical preparations for use in connection with humans for the prevention of diseases of the mastoid process; Pharmaceutical preparations for use in connection with humans for the treatment of diseases of the circulatory system; Pharmaceutical preparations for use in connection with humans for the prevention of diseases of the circulatory system; Pharmaceutical preparations for use in connection with humans for the treatment of diseases of the respiratory system; Pharmaceutical preparations for use in connection with humans for the prevention of diseases of the respiratory system; Pharmaceutical preparations for use in connection with humans for the treatment of diseases of the digestive system; Pharmaceutical preparations for use in connection with humans for the prevention of diseases of the digestive system; Pharmaceutical preparations for use in connection with humans for the treatment of diseases of the skin; Pharmaceutical preparations for use in connection with humans for the prevention of diseases of the skin; Pharmaceutical preparations for use in connection with humans for the treatment of diseases of subcutaneous tissue; Pharmaceutical preparations for use in connection with humans for the prevention of diseases of subcutaneous tissue; Pharmaceutical preparations for use in connection with humans for the treatment of diseases of the musculoskeletal system; Pharmaceutical preparations for use in connection with humans for the prevention of diseases of the musculoskeletal system; Pharmaceutical preparations for use in connection with humans for the treatment of diseases of the connective tissue; Pharmaceutical preparations for use in connection with humans for the prevention of diseases of the connective tissue; Pharmaceutical preparations for use in connection with humans for the treatment of diseases of the genitourinary system; Pharmaceutical preparations for use in connection with humans for the prevention of diseases of the genitourinary system; Pharmaceutical preparations for use in connection with humans for the treatment of infectious diseases and diabetes occurred in pregnancy; Pharmaceutical preparations for use in connection with humans for the prevention of infectious diseases and diabetes occurred in pregnancy; Pharmaceutical preparations for use in connection with humans for the treatment of infectious diseases occurred in childbirth; Pharmaceutical preparations for use in connection with humans for the prevention of infectious diseases occurred in childbirth; Pharmaceutical preparations for use in connection with humans for the treatment of infectious diseases occurred in the puerperium; Pharmaceutical preparations for use in connection with humans for the prevention of infectious diseases occurred in the puerperium; Pharmaceutical preparations for use in connection with humans for the treatment of nutritional deficiency conditions originating in the perinatal period; Pharmaceutical preparations for use in connection with humans for the prevention of nutritional deficiency conditions originating in the perinatal period; Pharmaceutical preparations for use in connection with humans for the treatment of congenital malformations; Pharmaceutical preparations for use in connection with humans for the prevention of congenital malformations; Pharmaceutical preparations for use in connection with humans for the treatment of deformations; Pharmaceutical preparations for use in connection with humans for the prevention of deformations; Pharmaceutical preparations for use in connection with humans for the treatment of chromosomal abnormalities; Pharmaceutical preparations for use in connection with humans for the prevention of chromosomal abnormalities; Prescribed pharmaceutical preparations for the treatment of infectious diseases; Prescribed pharmaceutical preparations for the prevention of infectious diseases; Prescribed pharmaceutical preparations for the treatment of parasitic diseases; Prescribed pharmaceutical preparations for the prevention of parasitic diseases; Prescribed pharmaceutical preparations for the treatment of neoplasms; Prescribed pharmaceutical preparations for the prevention of neoplasms; Prescribed pharmaceutical preparations for the treatment of diseases of the blood; Prescribed pharmaceutical preparations for the prevention of diseases of the blood Prescribed pharmaceutical preparations for the treatment of diseases of blood-forming organs; Prescribed pharmaceutical preparations for the prevention of diseases of blood-forming organs; Prescribed pharmaceutical preparations for the treatment of diseases of certain disorders involving the immune mechanism; Prescribed pharmaceutical preparations for the prevention of diseases of certain disorders involving the immune mechanism; Prescribed pharmaceutical preparations for the treatment of endocrine diseases; Prescribed pharmaceutical preparations for the prevention of endocrine diseases; Prescribed pharmaceutical preparations for the treatment of nutritional diseases; Prescribed pharmaceutical preparations for the prevention of nutritional diseases; Prescribed pharmaceutical preparations for the treatment of metabolic diseases; Prescribed pharmaceutical preparations for the prevention of metabolic diseases; Prescribed pharmaceutical preparations for the treatment of mental disorders; Prescribed pharmaceutical preparations for the prevention of mental disorders; Prescribed pharmaceutical preparations for the treatment of behavioural disorders; Prescribed pharmaceutical preparations for the prevention of behavioural disorders; Prescribed pharmaceutical preparations for the treatment of diseases of the nervous system; Prescribed pharmaceutical preparations for the prevention of diseases of the nervous system; Prescribed pharmaceutical preparations for the treatment of diseases of the eye; Prescribed pharmaceutical preparations for the prevention of diseases of the eye; Prescribed pharmaceutical preparations for the treatment of diseases of eye adnexa; Prescribed pharmaceutical preparations for the prevention of diseases of eye adnexa; Prescribed pharmaceutical preparations for the treatment of diseases of the ear; Prescribed pharmaceutical preparations for the prevention of diseases of the ear; Prescribed pharmaceutical preparations for the treatment of diseases of the mastoid process; Prescribed pharmaceutical preparations for the prevention of diseases of the mastoid process; Prescribed pharmaceutical preparations for the treatment of diseases of the circulatory system; Prescribed pharmaceutical preparations for the prevention of diseases of the circulatory system; Prescribed pharmaceutical preparations for the treatment of diseases of the respiratory system; Prescribed pharmaceutical preparations for the prevention of diseases of the respiratory system; Prescribed pharmaceutical preparations for the treatment of diseases of the digestive system; Prescribed pharmaceutical preparations for the prevention of diseases of the digestive system; Prescribed pharmaceutical preparations for the treatment of diseases of the skin; Prescribed pharmaceutical preparations for the prevention of diseases of the skin; Prescribed pharmaceutical preparations for the treatment of diseases of subcutaneous tissue; Prescribed pharmaceutical preparations for the prevention of diseases of subcutaneous tissue; Prescribed pharmaceutical preparations for the treatment of diseases of the musculoskeletal system; Prescribed pharmaceutical preparations for the prevention of diseases of the musculoskeletal system; Prescribed pharmaceutical preparations for the treatment of diseases of the connective tissue; Prescribed pharmaceutical preparations for the prevention of diseases of the connective tissue; Prescribed pharmaceutical preparations for the treatment of diseases of the genitourinary system; Prescribed pharmaceutical preparations for the prevention of diseases of the genitourinary system; Prescribed pharmaceutical preparations for the treatment of infectious diseases and diabetes occurred in pregnancy; Prescribed pharmaceutical preparations for the prevention of infectious diseases and diabetes occurred in pregnancy; Prescribed pharmaceutical preparations for the treatment of infectious diseases occurred in childbirth; Prescribed pharmaceutical preparations for the prevention of infectious diseases occurred in childbirth; Prescribed pharmaceutical preparations for the treatment of infectious diseases occurred in the puerperium; Prescribed pharmaceutical preparations for the prevention of infectious diseases occurred in the puerperium; Prescribed pharmaceutical preparations for the treatment of nutritional deficiency conditions originating in the perinatal period; Prescribed pharmaceutical preparations for the prevention of nutritional deficiency conditions originating in the perinatal period; Prescribed pharmaceutical preparations for the treatment of congenital malformations; Prescribed pharmaceutical preparations for the prevention of congenital malformations; Prescribed pharmaceutical preparations for the treatment of deformations; Prescribed pharmaceutical preparations for the prevention of deformations; Prescribed pharmaceutical preparations for the treatment of chromosomal abnormalities; Prescribed pharmaceutical preparations for the prevention of chromosomal abnormalities; Biological pharmaceutical preparations for the treatment of infectious diseases; Biological pharmaceutical preparations for the prevention of infectious diseases; Biological pharmaceutical preparations for the treatment of parasitic diseases; Biological pharmaceutical preparations for the prevention of parasitic diseases; Biological pharmaceutical preparations for the treatment of neoplasms; Biological pharmaceutical preparations for the prevention of neoplasms; Biological pharmaceutical preparations for the treatment of diseases of the blood; Biological pharmaceutical preparations for the prevention of diseases of the blood; Biological pharmaceutical preparations for the treatment of diseases of blood-forming organs; Biological pharmaceutical preparations for the prevention of diseases of blood-forming organs; Biological pharmaceutical preparations for the treatment of diseases of certain disorders involving the immune mechanism; Biological pharmaceutical preparations for the prevention of diseases of certain disorders involving the immune mechanism; Biological pharmaceutical preparations for the treatment of endocrine diseases; Biological pharmaceutical preparations for the prevention of endocrine diseases; Biological pharmaceutical preparations for the treatment of nutritional diseases; Biological pharmaceutical preparations for the prevention of nutritional diseases; Biological pharmaceutical preparations for the treatment of metabolic diseases; Biological pharmaceutical preparations for the prevention of metabolic diseases; Biological pharmaceutical preparations for the treatment of mental disorders; Biological pharmaceutical preparations for the prevention of mental disorders; Biological pharmaceutical preparations for the treatment of behavioural disorders; Biological pharmaceutical preparations for the prevention of behavioural disorders; Biological pharmaceutical preparations for the treatment of diseases of the nervous system; Biological pharmaceutical preparations for the prevention of diseases of the nervous system; Biological pharmaceutical preparations for the treatment of diseases of the eye; Biological pharmaceutical preparations for the prevention of diseases of the eye; Biological pharmaceutical preparations for the treatment of diseases of eye adnexa; Biological pharmaceutical preparations for the prevention of diseases of eye adnexa; Biological pharmaceutical preparations for the treatment of diseases of the ear; Biological pharmaceutical preparations for the prevention of diseases of the ear; Biological pharmaceutical preparations for the treatment of diseases of the mastoid process; Biological pharmaceutical preparations for the prevention of diseases of the mastoid process; Biological pharmaceutical preparations for the treatment of diseases of the circulatory system; Biological pharmaceutical preparations for the prevention of diseases of the circulatory system; Biological pharmaceutical preparations for the treatment of diseases of the respiratory system; Biological pharmaceutical preparations for the prevention of diseases of the respiratory system; Biological pharmaceutical preparations for the treatment of diseases of the digestive system; Biological pharmaceutical preparations for the prevention of diseases of the digestive system; Biological pharmaceutical preparations for the treatment of diseases of the skin; Biological pharmaceutical preparations for the prevention of diseases of the skin; Biological pharmaceutical preparations for the treatment of diseases of subcutaneous tissue; Biological pharmaceutical preparations for the prevention of diseases of subcutaneous tissue; Biological pharmaceutical preparations for the treatment of diseases of the musculoskeletal system; Biological pharmaceutical preparations for the prevention of diseases of the musculoskeletal system; Biological pharmaceutical preparations for the treatment of diseases of the connective tissue; Biological pharmaceutical preparations for the prevention of diseases of the connective tissue; Biological pharmaceutical preparations for the treatment of diseases of the genitourinary system; Biological pharmaceutical preparations for the prevention of diseases of the genitourinary system; Biological pharmaceutical preparations for the treatment of infectious diseases and diabetes occurred in pregnancy; Biological pharmaceutical preparations for the prevention of infectious diseases and diabetes occurred in pregnancy; Biological pharmaceutical preparations for the treatment of infectious diseases occurred in childbirth; Biological pharmaceutical preparations for the prevention of infectious diseases occurred in childbirth; Biological pharmaceutical preparations for the treatment of infectious diseases occurred in the puerperium; Biological pharmaceutical preparations for the prevention of infectious diseases occurred in the puerperium; Biological pharmaceutical preparations for the treatment of nutritional deficiency conditions originating in the perinatal period; Biological pharmaceutical preparations for the prevention of nutritional deficiency conditions originating in the perinatal period; Biological pharmaceutical preparations for the treatment of congenital malformations; Biological pharmaceutical preparations for the prevention of congenital malformations; Biological pharmaceutical preparations for the treatment of deformations; Biological pharmaceutical preparations for the prevention of deformations; Biological pharmaceutical preparations for the treatment of chromosomal abnormalities; Biological pharmaceutical preparations for the prevention of chromosomal abnormalities;bandages for dressingsSECTION 71 - CANCELLED—
010Apparatus for drug administration, namely, drug delivery systems, injector, autoinjector; Therapeutic inhalers, sold empty; High frequency electromagnetic therapy apparatus; Oxygen inhalaters for therapeutic purposes; Ultraviolet radiator units for therapeutic purposes; Defibrillators; Pneumothorax apparatus, namely, medical apparatus for diagnosing or treating respiratory conditions; Heart pacemakers; Mercury arc lamp units for therapeutic purposes; Infrared radiator units for therapeutic purposes; Puncture apparatus for therapeutic purposes, namely, medical devices for closing wounds; Lavage apparatus for therapeutic purposes, namely, apparatus for washing out body cavities; Carbon arc lamp units for therapeutic purposes; Injection syringes, syringe barrels; Injection needles; Infusion apparatus for therapeutic purposes, namely, infusion pumps for delivering measured amounts of solutions into the bloodstream over time; Ultrasonic therapy machines and apparatus; Short wave therapy machines and apparatus; Therapeutic bath apparatus and instruments, namely, appliances for washing body cavities; Massage apparatus for medical purposes; Low frequency electric therapy apparatus; Static electric therapy apparatus; Dialyzers, namely, blood component separation apparatus for medical purposes; Acupuncture needles; Sprayers for medical purposes, namely, drug delivery sprayers sold empty; Suture apparatus for medical purposes, namely, suture needles and suture materials; Radioisotope therapy apparatus and instruments; Incubators for babies; Blood transfusion apparatus; Containers and trays specially designed for transporting and holding pharmaceuticals; Injection device for pharmaceuticals; Injection instruments without needles; Injection instruments with needlesSECTION 71 - CANCELLED—
035Providing information concerning commercial sales in the field of pharmaceuticalsSECTION 71 - CANCELLED—
040Custom manufacture of pharmaceuticalsSECTION 71 - CANCELLED—
042Pharmaceutical research; pharmaceutical developmentSECTION 71 - CANCELLED—
044Pharmaceutical information services provided via the Internet, namely, providing information relating to diagnostic, prophylactic and therapeutic properties of pharmaceuticals; medical information services provided via the Internet; providing medical informationSECTION 71 - CANCELLED—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

DateCodeEventWhat it means
Oct 6, 2023RNWLINTERNATIONAL REGISTRATION RENEWED—
Jun 6, 2023FINPFINAL DECISION TRANSACTION PROCESSED BY IB—
Apr 14, 2023XXSSGENERIC MADRID TRANSACTION SENT TO IB—
Apr 14, 2023INNAINVALIDATION REVIEWED - NO ACTION REQUIRED BY OFFICE—
Apr 14, 2023XXCRGENERIC MADRID TRANSACTION CREATED—
Jan 15, 2023FINOFINAL DECISION TRANSACTION PROCESSED BY IB—
Oct 11, 2022INTRTOTAL INVALIDATION OF REG EXT PROTECTION CREATED—
May 30, 2022GPNXNOTIFICATION PROCESSED BY IB—
Mar 21, 2022RFNTREFUSAL PROCESSED BY IB—
Feb 11, 2022C71TCANCELLED SECTION 71—
Jan 31, 2016FINOFINAL DECISION TRANSACTION PROCESSED BY IB—
Dec 15, 2015XXSSGENERIC MADRID TRANSACTION SENT TO IB—
Dec 15, 2015XXCRGENERIC MADRID TRANSACTION CREATED—
Oct 28, 2015FICRFINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB—
Oct 20, 2015CORRCORRECTION FROM IB ENTERED - NO REVIEW REQUIRED—
Oct 9, 2015CRCVCORRECTION TRANSACTION RECEIVED FROM IB—
Jul 28, 2015R.PRREGISTERED-PRINCIPAL REGISTERYour trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive.
Jul 17, 2015OPNXNOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB—
Jul 1, 2015OPNSNOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB—
Jul 1, 2015OPNRNOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB—
May 12, 2015PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
May 8, 2015GPNXNOTIFICATION PROCESSED BY IB—
Apr 22, 2015OPNSNOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB—
Apr 22, 2015OP2RNOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB—
Apr 22, 2015NPUBNOTICE OF PUBLICATION—
Apr 7, 2015PREVLAW OFFICE PUBLICATION REVIEW COMPLETED—
Apr 7, 2015ALIEASSIGNED TO LIE—
Mar 20, 2015CNEAEXAMINERS AMENDMENT MAILED—
Mar 19, 2015CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Mar 19, 2015XAECEXAMINER'S AMENDMENT ENTERED—
Mar 19, 2015CNEAEXAMINERS AMENDMENT -WRITTEN—
Feb 6, 2015CNFRFINAL REFUSAL MAILEDA final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon.
Feb 5, 2015CNFRFINAL REFUSAL WRITTENA final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon.
Jan 16, 2015TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Jan 15, 2015CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Jan 15, 2015TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Jul 22, 2014CNRTNON-FINAL ACTION MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jul 21, 2014CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Jun 30, 2014TEMETEAS/EMAIL CORRESPONDENCE ENTERED—
Jun 30, 2014CRFACORRESPONDENCE RECEIVED IN LAW OFFICE—
Jun 19, 2014ALIEASSIGNED TO LIE—
Jun 11, 2014TROATEAS RESPONSE TO OFFICE ACTION RECEIVEDThis event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action.
Apr 25, 2014RFNPREFUSAL PROCESSED BY IB—
Mar 25, 2014RFCSNON-FINAL ACTION MAILED - REFUSAL SENT TO IB—
Mar 25, 2014RFRRREFUSAL PROCESSED BY MPU—
Mar 25, 2014RFCRNON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW—
Mar 24, 2014CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Mar 24, 2014DOCKASSIGNED TO EXAMINER—
Feb 4, 2014MAFRAPPLICATION FILING RECEIPT MAILED—
Jan 31, 2014NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Jan 30, 2014REPRSN ASSIGNED FOR SECT 66A APPL FROM IB—

Frequently asked questions

Related guidance